BioSpace News Archive

The Exclusive Research Report on “ADME-Tox Screening Systems Market with Industry-Primary Research, Secondary Research, Product Research, Revenue, Emerging Trends and Top Growing Companies 2020-2029”.

New York State Attorney General Supports Company’s Proposed Global Opioid Settlement; Joining 47 Other State and U.S. Territory Attorneys General

Maxar Technologies (NYSE:MAXR) (TSX:MAXR), a trusted partner and innovator in Earth Intelligence and Space Infrastructure, is closely monitoring and proactively mitigating a number of risks related to the Coronavirus (COVID-19), and is following the guidance of the World Health Organization, Centers for Disease Control and other government agencies.

Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial-stage plasma-derived biopharmaceutical company, today provided an update on progress related to its proprietary hyper-immunoglobulin (IgGs) product portfolio and platform technology.

TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the company will report 2019 fourth quarter and full year financial results on Friday, March 27, 2020, before market open

Bio-Path Holdings, Inc. announced that the Audit Committee of the Company’s Board of Directors approved the appointment of Ernst & Young LLP as the Company’s new independent registered public accounting firm, replacing former auditor, BDO USA, LLP.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company focused on gastrointestinal diseases, today provided an update on its clinical development programs for opaganib (Yeliva®, ABC294640)2

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that it has received the final minutes from a meeting with the U.S. Food and Drug Administration (FDA) held on February 5, 2020.

Pascal Biosciences Inc. has entered into a Term Sheet with SōRSE Technology to develop Pascal’s cannabinoid programs.

Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, today announced a filing with the Respiratory Diseases Branch of the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), to evaluate AT-100 (rhSP-D) as a therapeutic for the novel coronavirus (COVID-19).